Aditya H. Gaur MD
Associate Professor, Preventive Medicine, University of Tennessee Health Science Center College of Medicine
Join to view full profile
262 Danny Thomas PlMemphis, TN 38105
Phone+1 888-226-4343
Dr. Gaur is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Tennessee College of MedicineFellowship, Pediatric Infectious Diseases, 1999 - 2003
Geisinger Health SystemResidency, Pediatrics, 1996 - 1999
Government Medical College GujuratClass of 1994
Certifications & Licensure
TN State Medical License 2004 - 2028
PA State Medical License 1999 - 2004
American Board of Pediatrics Pediatrics- American Board of Pediatrics Pediatric Infectious Diseases
Clinical Trials
- Directly Observed Therapy for HIV Infected Adolescents
- Project ACCEPT: Engaging Newly Diagnosed HIV+ Youth in Care
- Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants Start of enrollment: 2013 Aug 26
Publications & Presentations
PubMed
- Prospective HIV RNA screening with long-acting cabotegravir pre-exposure prophylaxis in HPTN 083.Raphael J Landovitz, Jessica M Fogel, Fei Gao, Brett Hanscom, Estelle Piwowar-Manning
Clinical Infectious Diseases. 2026-04-27 - 2 citationsEfficacy and safety of lenacapavir, teropavimab, and zinlirvimab: week-26 primary outcome results from a multicentre, open-label, randomised, active-controlled, phase ...Onyema Ogbuagu, Aditya Gaur, James H McMahon, Linda Gorgos, Javier O Morales-Ramirez
The Lancet. Microbe. 2026-03-01 - 1 citationsAcceptability and tolerability of long-acting injectable cabotegravir-rilpivirine in adolescents with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multicentre, ope...Elizabeth D Lowenthal, Jennifer Chapman, Kristin Baltrusaitis, Grace Kovic, Sanjna Merchant
The Lancet. HIV. 2026-02-01
Journal Articles
- Effect of Levofloxacin Prophylaxis on Bacteremia in Children with Acute Leukemia or Undergoing Hematopoietic Stem Cell TransplantationL Charles Bailey, Aditya H Gaur, Michael L Nieder, Michael Green, Christopher C Dvorak, JAMA
Press Mentions
Here’s What We Know About the Johnson & Johnson VaccineFebruary 25th, 2021- Johnson & Johnson Covid-19 Vaccine Is Safe and Effective, FDA Analysis FindsFebruary 24th, 2021
- COVID-19 Vaccine Trial Happening in Memphis Still Needs More ParticipantsDecember 4th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
